Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19

Raef Fadel, Austin R Morrison, Amit Vahia, Zachary R Smith, Zohra Chaudhry, Pallavi Bhargava, Joseph Miller, Rachel M Kenney, George Alangaden, Mayur S Ramesh, Henry Ford COVID-19 Management Task Force, Varidhi Nauriyal, Jayanth Lakshmikanth, Asif Abdul Hamed, Owais Nadeem, Kristin Griebe, Joseph M Johnson, Patrick Bradley, Junior Uduman, Sara Hegab, Jennifer Swiderek, Amanda Godfrey, Jeffrey Jennings, Jayna Gardner-Gray, Adam Ackerman, Jonathan Lezotte, Joseph Ruhala, Linoj Samuel, Robert J Tibbetts, Indira Brar, John McKinnon, Geehan Suleyman, Nicholas Yared, Erica Herc, Jonathan Williams, Odaliz Abreu Lanfranco, Anne Chen, Marcus Zervos, Eric Scher, Raef Fadel, Austin R Morrison, Amit Vahia, Zachary R Smith, Zohra Chaudhry, Pallavi Bhargava, Joseph Miller, Rachel M Kenney, George Alangaden, Mayur S Ramesh, Henry Ford COVID-19 Management Task Force, Varidhi Nauriyal, Jayanth Lakshmikanth, Asif Abdul Hamed, Owais Nadeem, Kristin Griebe, Joseph M Johnson, Patrick Bradley, Junior Uduman, Sara Hegab, Jennifer Swiderek, Amanda Godfrey, Jeffrey Jennings, Jayna Gardner-Gray, Adam Ackerman, Jonathan Lezotte, Joseph Ruhala, Linoj Samuel, Robert J Tibbetts, Indira Brar, John McKinnon, Geehan Suleyman, Nicholas Yared, Erica Herc, Jonathan Williams, Odaliz Abreu Lanfranco, Anne Chen, Marcus Zervos, Eric Scher

Abstract

Background: There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19.

Methods: We conducted a single pretest, single posttest quasi-experiment in a multicenter health system in Michigan from 12 March to 27 March 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary composite endpoint of escalation of care from ward to intensive care unit (ICU), new requirement for mechanical ventilation, and mortality. All patients had at least 14 days of follow-up.

Results: We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively. The composite endpoint occurred at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005). This treatment effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length of stay was also observed in the early corticosteroid group (5 vs 8 days, P < .001). Multivariate regression analysis demonstrated an independent reduction in the composite endpoint at 14-days controlling for other factors (adjusted odds ratio: 0.41; 95% confidence interval, .22 - .77).

Conclusions: An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation of care and improved clinical outcomes.

Clinical trials registration: NCT04374071.

Keywords: COVID-19; Corticosteroids; SARS-COV-2; coronavirus; outcomes.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Number of patients screened and included in the trial.

References

    1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases and latest updates. Available at: Accessed 7 April 2020
    1. Centers for Disease Control and Prevention. COVID-NET: COVID-19 associated hospitalization surveillance network. Available at: . Accessed 8 April 2020.
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; Feb 28. doi:10.1056/NEJMoa2002032. [Epub ahead of print]
    1. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39:405–7.
    1. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol 2020; 25:108393.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Tian S, Hu W, Niu L, et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020; pii:S1556-0864(20)30132–5. doi: 10.1016/j.jtho.2020.02.010. [Epub ahead of print]
    1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8:420–2.
    1. Zhou Y, Fu B, Zhang X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in Severe COVID-19 patients. Natl Sci Rev nwaa041. doi:10.1093/nsr/nwaa041.
    1. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis 2020; 7:ofaa105.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473–5.
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585. [Epub ahead of print]
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; pii:S2213-2600(20)30079-5.
    1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print]
    1. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020. doi: 10.1097/CCM.0000000000004363. [Epub ahead of print]
    1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020. doi: 10.1056/NEJMoa2001282. [Epub ahead of print]
    1. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395:683–4.
    1. Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation 2013; 84:465–70.
    1. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:762–74.
    1. Ranieri V, Rubenfeld GD, Thompson B, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526–33.
    1. Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2:1–38.
    1. White DB, Lo B. A framework for rationing ventilators and critical care beds during the COVID-19 pandemic. JAMA 2020. doi: 10.1001/jama.2020.5046. [Epub ahead of print]
    1. Ranney ML, Griffeth V, Jha AK. Critical supply shortages - the need for ventilators and personal protective equipment during the Covid-19 pandemic. N Engl J Med 2020; 382:e41.
    1. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2. Available at: Accessed 3 April 2020).
    1. Arabi YM, Mandourah Y, Al-Hameed F, et al. ; Saudi Critical Care Trial Group Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 2018; 197:757–67.
    1. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006; 129:1441–52.
    1. Xu K, Chen Y, Yhan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis 2020. ciaa351. doi:10.1093/cid/ciaa351.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться